null Kevin Schwartzman, MD MPH

Senior Scientist, RI-MUHC , 5252 de Maisonneuve

Translational Research in Respiratory Diseases Program

Centre for Outcomes Research and Evaluation

Professor, Department of Medicine, Faculty of Medicine and Health Sciences, McGill University

Department of Medicine, Division of Respiratory Medicine, MUHC



tuberculosis • epidemiology • public health • respiratory disease • health economics • digital adherence technologies

Research Focus

My research focuses on designing more effective and cost-effective interventions for tuberculosis care and prevention, using predictions based on current knowledge of benefits, costs, and impacts including those on patients' quality of life. My current research focuses on potential tuberculosis prevention strategies for migrants to Canada using computer simulation techniques. I also consider ethical dimensions of these strategies.

Selected Publications

Click on Pubmed to see my current publications list

  • Domestic returns from investment in the control of tuberculosis in other countries. Schwartzman K, Oxlade O, Barr RG, Grimard F, Acosta I, Baez J, Ferreira E, Melgen RE, Morose W, Salgado AC, Jacquet V, Maloney S, Laserson K, Mendez AP, Menzies D. N Engl J Med. 2005 Sep 8;353(10):1008-20. doi: 10.1056/NEJMsa043194. PMID: 16148286.

  • The impact of tuberculosis on health utility: a longitudinal cohort study. Bauer M, Ahmed S, Benedetti A, Greenaway C, Lalli M, Leavens A, Menzies D, Vadeboncoeur C, Vissandjée B, Wynne A, Schwartzman K. Qual Life Res. 2015 Jun;24(6):1337-49. doi: 10.1007/s11136-014-0858-6. Epub 2014 Nov 13. PMID: 25391490.

  • Evaluating the potential costs and impact of digital health technologies for tuberculosis treatment support. Nsengiyumva NP, Mappin-Kasirer B, Oxlade O, Bastos M, Trajman A, Falzon D, Schwartzman K. Eur Respir J. 2018 Nov 1;52(5):1801363. doi: 10.1183/13993003.01363-2018. Print 2018 Nov. Free PMC article. PMID: 30166325.

  • The potential impact and cost-effectiveness of tobacco reduction strategies for tuberculosis prevention in Canadian Inuit communities. N'Diaye DS, Nsengiyumva NP, Uppal A, Oxlade O, Alvarez GG, Schwartzman K. BMC Med. 2019 Feb 4;17(1):26. doi: 10.1186/s12916-019-1261-5. Free PMC article. PMID: 30712513.

  • Treatment of latent infection to achieve tuberculosis elimination in low-incidence countries. Campbell JR, Dowdy D, Schwartzman K. PLoS Med. 2019 Jun 6;16(6):e1002824. doi: 10.1371/journal.pmed.1002824. eCollection 2019 Jun. Free PMC article. Review. PMID: 31170161.